Company intelligence / Profile preview

OncoEthix

Lausanne, Vaud, Switzerlandmerck.com ↗

Ownership: Private
Development stage: Phase 1

Overview

OncoEthix’s lead product, OTX015, demonstrated early promising activity in hematological cancers and was being evaluated in Phase 1b trials at the time of Merck’s acquisition. The compound is an oral BET inhibitor with potential first-in-class status. No later-stage or commercial results were reported prior to acquisition.

Therapeutic areas: Oncology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

OTX015

Phase 1

Indications: Hematological malignancies, Advanced solid tumors

Partnerships

In-license agreement with Mitsubishi Tanabe Pharma Corporation for OTX015

Beyond the preview

Go deeper on OncoEthix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OncoEthix.

Explore the full profile